Vir Biotechnology (VIR) Q2 Profit Turn Raises The Question Of Whether Shares Are Still Cheap
What the latest Vir Biotechnology earnings tell you
Vir Biotechnology (VIR) has drawn fresh attention after its second quarter 2026 earnings update, which showed revenue of US$238.95 million and net income of US$80.08 million, compared with a net loss a year earlier.
See our latest analysis for Vir Biotechnology.
Vir Biotechnology shares trade at US$9.24 after a 1-day share price return of 2.67% and a year-to-date share price return of 55.56%, while the 1-year total shareholder return of 104.42% contrasts with weaker 3 and 5 year total shareholder returns, suggesting recent momentum has picked up from a much lower base.
If strong recent gains in Vir Biotechnology have caught your eye, this could be a good moment to widen your watchlist toward other healthcare-focused AI opportunities such as the 44 healthcare AI stocks
Bulls see Vir Biotechnology’s sharp swing to quarterly profit and strong 1 year return as the start of a turnaround. Bears point to multi year losses and a weak longer term track record. Which side does today’s valuation support?
Most Popular Narrative: 57.1% Undervalued
The most followed narrative on Vir Biotechnology puts fair value at $21.56 a share, well above the latest close of $9.24, which highlights a clear tension between current pricing and longer term expectations.
The analysts have a consensus price target of $21.56 for Vir Biotechnology based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $16.0.
Want to see what sits behind that gap between price and fair value? The narrative focuses on rapid revenue expansion, higher margins and a rich future earnings multiple. Curious which specific forecasts carry the most weight in that story?
Result: Fair Value of $21.56 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh up real risks, including ongoing net losses of US$251.68 million and dependence on unproven therapies clearing clinical and regulatory hurdles.
Find out about the key risks to this Vir Biotechnology narrative.
Another view on Vir Biotechnology valuation
The analyst narrative frames Vir Biotechnology as undervalued relative to a US$21.56 fair value, yet the current P/S ratio of 5.2x tells a more cautious story. The stock trades well below the US Biotechs industry average of 11.4x, but far above its own fair ratio of 0.6x, which points to meaningful valuation risk if sentiment cools.
That gap suggests investors are already paying a premium for future success despite ongoing losses. The key question is whether you see today’s price as an early entry into a peer discount, or a rich bet relative to the fair ratio the market could move toward over time.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
The mixed signals around Vir Biotechnology can make the story feel finely balanced, so it makes sense to review the details quickly and form your own stance. To understand what concerns other investors most, start with the 2 important warning signs
Looking for more Vir Biotechnology investment ideas?
If Vir Biotechnology has sharpened your focus on where to put fresh capital, do not stop here. The right shortlist today could shape your returns for years.
- Spot potential standouts early by checking the screener containing 18 high quality undiscovered gems that combine quality fundamentals with less crowded ownership.
- Prioritise strength and resilience through the solid balance sheet and fundamentals stocks screener (50 results) so you are not caught out by hidden financial weak points.
- Lean toward stability with the income focused 10 dividend fortresses and see which companies currently offer higher yields with support from their cash flows.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com